Trials / Terminated
TerminatedNCT01923389
Multiple Dose Study Of PF-05231023 In Obese Adult Subjects
A Phase 1, Placebo-Controlled, Randomized Trial To Assess The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Intravenous Doses Of PF-05231023 In Obese Adult Subjects
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 4 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 21 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This is a trial in obese subjects to study the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple doses of PF-05231023.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Placebo | 0.9% w/v sodium chloride injection, United States Pharmacopeia (USP), twice a week for 4 weeks. |
| DRUG | 100 mg PF-05231023 | 100 mg IV infusion twice a week for 4 weeks |
Timeline
- Start date
- 2013-09-01
- Primary completion
- 2013-12-01
- Completion
- 2013-12-01
- First posted
- 2013-08-15
- Last updated
- 2014-09-17
- Results posted
- 2014-09-17
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01923389. Inclusion in this directory is not an endorsement.